Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Yesterday
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.

Apremilast improves QoL in adults with scalp psoriasis

Elaine Soliven
24 Nov 2020

Treatment with apremilast led to significantly improved patient-reported quality of life (QoL) outcomes in patients with moderate-to-severe plaque psoriasis of the scalp, according to the STYLE* study presented at EADV 2020.

This phase III, multicentre, double-blind, placebo-controlled trial evaluated 303 patients with moderate-to-severe scalp psoriasis** and plaque psoriasis***. Patients were randomly assigned in a 2:1 ratio to receive either apremilast 30 mg twice daily (n=201; mean age 47.0 years) or placebo (n=102; mean age 46.7 years) for 16 weeks. Dermatology Life Quality Index (DLQI) scores were used to assess health-related QoL at 16 weeks. [EADV 2020, abstract P1345-1445]

At week 16, patients who received apremilast had a significantly greater improvement in DLQI total score, indicating a better QoL, compared with placebo (mean change from baseline, -6.7 vs -3.9; p<0.0001).

Significantly more patients in the apremilast group also achieved a ≥4 point reduction in DLQI MCID+ from baseline to week 16 (76.1 percent vs 47.9 percent; p<0.0001) than those in the placebo group.

Although not significant, apremilast recipients also achieved a numerically higher DLQI subscale scores for symptoms and feelings (-2.0 vs -0.9), daily activities (-1.6 vs -0.7), leisure (-1.1 vs -0.9), work and school (-1.0 vs -0.7), and overall treatment (-0.4 vs -0.3) compared with placebo recipients.

In a post hoc analysis, a higher percentage of apremilast-treated patients achieved a DLQI score of 0 or 1 for DLQI total score (23.2 percent vs 6.0 percent) and several individual DLQI item scores, such as Q1++ (62.0 percent vs 41.0 percent), Q2++ (64.2 percent vs 40.6 percent), and Q3# (67.7 percent vs 50.0 percent), compared with placebo-treated patients.

“[The] achievement of DLQI score of 0 or 1 … with apremilast … increased overtime and was concordant with [Scalp Physician’s Global Assessment] (ScPGA) score of 0 or 1,” said study co-investigator Dr Linda Stein Gold from Henry Ford Health System in West Bloomfield, Michigan, US.

“In STYLE, patients with moderate-to-severe psoriasis of the scalp experienced improvements in QoL outcomes, including many DLQI subscales and individual items assessing the impact of psoriasis on patients’ lives,” Gold concluded.

“Significant and clinically meaningful improvement in DLQI total score was observed in apremilast vs placebo at week 16,” she highlighted.

 

*STYLE: A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

**Scalp Physician’s Global Assessment (ScPGA) score of ≥3 (defined as moderate or greater); psoriasis-involved scalp surface area of ≥20 percent

***Psoriasis Area and Severity Index of ≥12; psoriasis-involved body surface area of ≥10 percent; static PGA of ≥3 (defined as moderate or greater)

+MCID: Minimal clinically important difference

++Q1: Itchy, sore, painful, stinging skin

++Q2: Embarrassed, self-conscious

#Q3: Interfered with shopping, home, yard

Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Yesterday
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.